Extension Protocol for Patients Previously Treated in Avapritinib Clinical Trials
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Avapritinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Blueprint Medicines
- 01 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Aug 2025.
- 01 Aug 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Aug 2025.
- 25 May 2021 Status changed from not yet recruiting to active, no longer recruiting.